Preventive cardiologyAbstractEffects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-Year Experience From the RIO-Europe Study

@article{Gaal2005PreventiveCO,
  title={Preventive cardiologyAbstractEffects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-Year Experience From the RIO-Europe Study},
  author={Luc F. van Gaal and Aila M. Rissanen and Andr{\'e} J. Scheen and Olivier Ziegler and Stephan R{\"o}ssner},
  journal={Acc Current Journal Review},
  year={2005},
  volume={14},
  pages={10}
}
Modification of Cardiometabolic Risk Through Cannabinoid Type-1 Receptor Antagonism
TLDR
Rimonabant is the first type-1 endocannabinoid receptor blocker that has been shown to improve the serum lipid profile, insulin and glucose levels, and blood pressure, and may prove to be a valuable adjunct in targeting obesity-related cardiovascular risk factors. Expand
[Prospects for the Use of Cannabinoid Receptor Ligands for the Treatment of Metabolic Syndrome and Atherosclerosis: Analysis of Experimental and Clinical Data].
TLDR
Experimental studies suggest that peripheral CB2 receptor agonists have antiatherogenic effect, and to validate the expediency of clinical research of CB2 receptors agonists in patients with atherosclerosis the comparative analysis of anti Atherogenic properties of cannabinoids should be performed. Expand
Effects of CB 1 antagonist on the control of metabolic functions in obese type 2 diabetic patients
Clinical reports (RIO trials) have shown that chronic administration of a CB-cannabinoid receptor antagonist (rimonabant) provides improvements of disturbed metabolic parameters observed inExpand
European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes.
TLDR
This research presents a novel and scalable approach to personalized medicine that addresses the challenges of direct injections of insulin to treat high blood pressure and type 2 diabetes. Expand
The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
TLDR
Rimonabant is a first-in-class, selective cannabinoid receptor type 1 (CB1 receptor) antagonist, which has been shown to reduce body weight consistently in obese and overweight individuals, and has been shows to exert beneficial actions on metabolic risk factors. Expand
The Role of the Endocannabinoid System in Managing Cardiometabolic Risk ( Part II ) : The Cardiovascular Consequences of Abdominal Adiposity and Cannabinoid-1 Receptor Blockade
The current global health threat posed by abdominal obesity is largely attributed to an excess of intra-abdominal adipose tissue. Recognized now as an important endocrine organ, intra-abdominalExpand
Endocannabinoid System and Cardiometabolic Risk
TLDR
There is a growing interest concerning the role of the endocannabinoid system in energy metabolism and how blockade of cannabinoid receptors (CB1) may optimize fat distribution, insulin sensitivity, and blood lipids to improve cardiovascular risk profile. Expand
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
TLDR
To determine whether weight loss and metabolic effects of the selective cannabinoid type 1 receptor antagonist rimonabant reduces progression of coronary disease in patients with abdominal obesity and the metabolic syndrome, the study failed to show an effect on disease progression. Expand
Rimonabant (Acomplia): The First Cannabinoid-1 Receptor Blocker for Obesity
TLDR
The goal of antiobesity treatment includes not only a reduction in weight but also in the disability and morbidity associated with obesity, thus leading to an improved quality of life for patients. Expand
Obesity and the Endocannabinoid System: Is There Still a Future for CB1 Antagonists in Obesity?
TLDR
The present review examines options that include peripheral-restricted cannabinoid CB1 receptor antagonists, dual ligands and combinatorial therapies using sub-effective doses of CB1 receptors that might be devoid of side effects. Expand
...
1
2
3
4
5
...